Piper Sandler analyst Kelsey Goodwin raised the firm’s price target on CG Oncology (CGON) to $70 from $55 and keeps an Overweight rating on the shares. Following a flurry of updates from companies across its coverage, the firm updating its 2026 Catalyst Tracker, as well as several models and price targets.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGON:
- Oncolytics appoints John McAdory as EVP, strategy and operations
- CG Oncology Expands At-The-Market Equity Offering Capacity
- Biotech Alert: Searches spiking for these stocks today
- CG Oncology price target raised to $66 from $62 at Truist
- CG Oncology price target raised to $82 from $55 at Goldman Sachs